Last reviewed · How we verify
NCT03542773
Targeted Imaging of Glutamate Carboxypeptidase II With DCFPyL-PET
Phase 1 trial testing 18F-DCFPyL Injection in Schwannomas in 38 participants. Completed in 1 May 2022.
1 May 2022
Quick facts
| Lead sponsor | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 38 |
| Start date | 6 February 2015 |
| Primary completion | 1 May 2022 |
| Estimated completion | 1 May 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- 18F-DCFPyL Injection
Conditions studied
- Schwannomas — all drugs for Schwannomas →
- Malignant Tumors — all drugs for Malignant Tumors →
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — full company profile →
Who can join
Adults 18 to 100, any sex, with Schwannomas or Malignant Tumors. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To use 18F-DCFPyL imaging agent and PET/CT to detect none prostate cancer solid malignancies and schwannoma tumors.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03542773
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of 18F-DCFPyL Injection
Trials testing the same drug.
- NCT03800784 — Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer · Phase 2, PHASE3 · withdrawn
- NCT03793543 — Test-Retest Reproducibility of 18F-DCFPyL PET/CT in the Evaluation of Patients With Metastatic Prostate Cancer · Phase 1 · completed
- NCT03471650 — Study of PSMA-targeted 18F-DCFPyL PET/CT for the Detection of Clinically Significant Prostate Cancer · Phase 2 · active not recruiting
Other recruiting trials for Schwannomas
Currently open trials in the same condition.
- NCT05684692 — Screening Trial for Pain Relief in Schwannomatosis (STARFISH) · Phase 2 · recruiting
Other Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins trials
Trials by the same sponsor.
- NCT07424222 — Ruxolitinib for Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (RISE) · Phase 1 · not yet recruiting
- NCT06210854 — Assessing Administration of pBI-11 Via Electroporation for the Treatment of Patients With HPV16/18+ · Phase 2 · not yet recruiting
- NCT07360119 — Total Pancreatectomy With Islet Autotransplantation (TPIAT) for High-Risk Patients With Pancreatic Tumors · NA · not yet recruiting
- NCT07140315 — DK222 Study at Hopkins · Phase 1 · recruiting
- NCT07071155 — Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Ove · EARLY_PHASE1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03542773 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Last refreshed: 11 January 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03542773.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing